Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to “Sell” at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

MCRB has been the subject of several other reports. Chardan Capital reiterated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Performance

Seres Therapeutics stock opened at $0.75 on Tuesday. The stock has a 50-day simple moving average of $0.84 and a 200 day simple moving average of $0.85. The stock has a market capitalization of $128.09 million, a P/E ratio of -3.26 and a beta of 2.11. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53.

Institutional Investors Weigh In On Seres Therapeutics

Hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its stake in shares of Seres Therapeutics by 77.2% during the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock worth $1,505,000 after purchasing an additional 788,762 shares during the period. Vontobel Holding Ltd. grew its holdings in Seres Therapeutics by 137.6% in the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 543,469 shares in the last quarter. Geode Capital Management LLC increased its position in Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 255,014 shares during the period. Charles Schwab Investment Management Inc. increased its position in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after buying an additional 222,771 shares during the period. Finally, FMR LLC lifted its holdings in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.